View the Latest: Benefits
Filter
-
-
Use of Physician and Supplier Services in Traditional Medicare
State Health Facts Indicator -
Use of Outpatient Hospital Services in Traditional Medicare
State Health Facts Indicator -
Use of Inpatient Hospital Services in Traditional Medicare
State Health Facts Indicator -
Use of Hospice Services in Traditional Medicare
State Health Facts Indicator -
Use of Home Health Services in Traditional Medicare
State Health Facts Indicator -
Medicaid Arrangements to Coordinate Medicare and Medicaid for Dual-Eligible Individuals
Issue BriefThis issue brief describes how state Medicaid programs are implementing arrangements aimed at coordinating Medicare and Medicaid for dual-eligible individuals.
-
Changes to Medicare Part D in 2024 and 2025 Under the Inflation Reduction Act and How Enrollees Will Benefit
Issue BriefThe Inflation Reduction Act of 2022 includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government, including a number of changes to the Medicare Part D drug benefit. This brief provides an overview of the Part D benefit design and Part D enrollee cost-sharing requirements in 2023 and changes coming in 2024 and 2025.
-
What Happens When COVID-19 Emergency Declarations End? Implications for Coverage, Costs, and Access
Issue BriefThis brief provides an overview of the major health-related COVID-19 federal emergency declarations that have been made since early on in the pandemic, summarizes the flexibilities triggered by each, and identifies the implications for their ending, related to coverage, costs, and payment for COVID-19 testing, treatments, and vaccines; Medicaid coverage and federal match rates; telehealth; access to medical countermeasures through FDA emergency use authorization (EUA); and other Medicaid, Medicare and private health insurance flexibilities.
-
Explaining the Prescription Drug Provisions in the Inflation Reduction Act
Issue BriefThe Inflation Reduction Act includes several provisions that will lower prescription drug costs for people with Medicare and reduce drug spending by the federal government. This brief summarizes these provisions and discusses the expected effects on people, program spending, and drug prices and innovation.